Summary
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract was one of the largest on record in the ongoing research for multiple myeloma treatment. PRA’s clinical team provided enhanced communication and site support, enabling PRA to streamline regulatory document collection to quickly activate sites. Approved by the FDA after a 4-month accelerated approval process, the drug is the first in a new class of anti-cancer agents called proteasome inhibitors.
Register to download
PRA Leads Novel Multiple Myeloma Drug Development
You may also be interested in:
resource
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…
page
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.
Webcast
Practical Implementation of Signal Detection in Iterative Benefit Risk Evaluation
This webcast with PRA Health Sciences' Jacinta Aniagolu-Johnson (Senior Director, Safety and Risk Management) explores how a well defined signal…